Nyrada Inc – Brain Injury Program Update

• In vitro safety and toxicology studies commenced 2H CY2022 and are tracking well
• No change to start of Phase I study, expected to commence in 1H CY2023, evaluating safety and tolerability of Nyrada’s brain injury drug in two indications, TBI and stroke
• Progression of formulation work necessary for intravenous drug administration causes slight delay to preclinical stroke model study; results expected Q1 CY2023